Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Tirzepatide: A Review in Type 2 Diabetes

Open access

Abstract

Tirzepatide (Mounjaro®), a first-in-class dual incretin agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, is approved for use as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM) in the USA, EU, Japan and other countries. It comes as single-dose prefilled pens and single-dose vials. In phase III SURPASS trials, once-weekly subcutaneous tirzepatide, as monotherapy or add-on-therapy to oral glucose-lowering medications and insulin, was superior to the GLP-1 receptor agonists (RAs) dulaglutide 0.75 mg and semaglutide 1 mg as well as basal and prandial insulin for glycaemic control and weight loss in adults with inadequately controlled T2DM. Tirzepatide was generally well tolerated, with a safety profile consistent with that of GLP-1 RAs. Tirzepatide was associated with a low risk of clinically significant or severe hypoglycaemia and no increased risk of major adverse cardiovascular events. Adverse events were mostly mild to moderate in severity, with the most common being gastrointestinal events including nausea, diarrhoea, decreased appetite and vomiting. In conclusion, tirzepatide is a valuable addition to the treatment options for T2DM.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-023-01992-4

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Goyal RJI. Type 2 diabetes. [updated 2023 June 23] In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2023. https://www.ncbi.nlm.nih.gov/pubmed/30020625. Accessed 19 Dec 2023.

Cited by

See all 51

Metadata

Authors
France, N. L., & Syed, Y. Y.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
France, Nicole L.
Venue
Drugs
Published
2024-02
Volume
84
Issue
2
Pages
227-238
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W4392773706
Cited by
51
References
40
Citations by year
2026: 14 · 2025: 28 · 2024: 9
FWCI
2.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by-nc)
  • Figshare
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, type 2 diabetes, GIP/GLP-1 receptor agonist, glycemic control, weight loss, dulaglutide, semaglutide, insulin, hypoglycemia, gastrointestinal adverse effects, drug safety, SURPASS trials, cardiovascular safety, pharmacokinetics, pharmacodynamics, drug interactions, dosage
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Tirzepatide, Adult, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucose, Humans, Hypoglycemic Agents, Insulin, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide: A Review in Type 2 Diabetes. https://app.cochat.ai/papers/10.1007/s40265-023-01992-4
The paper
France, N. L., & Syed, Y. Y. (2024). Tirzepatide: A Review in Type 2 Diabetes. Drugs. https://doi.org/10.1007/s40265-023-01992-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.